GSK enters exclusive license agreement with Hansoh for HS-20093 | GSK

- Hansoh's HS-20093 builds on GSK's oncology portfolio of clinical-stage antibody-drug conjugates, following earlier agreement for Hansoh's HS-20089 focused on gynaecologic cancers
- HS-20093 has...

Related Keywords

China ,Taiwan ,Macau ,United States ,Hong Kong ,American ,Chinese ,Hesham Abdullah ,Hansoh Pharma ,Eliza Sun ,American Society Of Clinical Oncology ,Global Head Oncology ,Clinical Oncology ,Executive Director ,Hart Scott Rodino Act ,Annual Report ,Markets ,